Blog Tag
5 articles tagged with Drug Development. The newest post is from Apr 29, 2026.
The FDA's latest move is not a promise to approve drugs faster by default. It is a sign that the agency wants to close the gap between what is happening inside a trial and when regulators can actually see it. That may sound subtle, but in biotech it matters a lot. Every month of delay affects capital, timelines, and the pace at which a company can move from one development phase to the next.
MOA stands for mechanism of action. It describes how a drug works in the body at the biological level. In biotech, MOA matters because it helps explain why a therapy might work, how it differs from competitors, and what kind of clinical effects it may produce.
Combination therapy means using two or more treatments together to treat a disease. In biotech, the term matters because many diseases are too complex to respond well to a single therapy alone. Combining drugs can improve efficacy, reduce resistance, or create a more durable clinical benefit.
Fast track designation is an FDA status intended to speed the development and review of drugs that treat serious conditions and fill an unmet medical need. In biotech, the designation matters because it can help promising therapies move more efficiently through the regulatory process.
Breakthrough therapy designation is an FDA status for drugs that show preliminary clinical evidence suggesting the therapy may offer substantial improvement over existing options for one or more serious or life-threatening conditions. In biotech, the designation matters because it can accelerate development and increase the level of interaction between the company and the FDA.
